Laura is the vice president of content for The American Journal of Managed Care® (AJMC®) and all its brands, including Population Health, Equity & Outcomes; Evidence-Based Oncology™; and The Center for Biosimilars®. She has been working on AJMC since 2014 and has been with AJMC’s parent company, MJH Life Sciences®, since 2011.
She has an MA in business and economic reporting from New York University. You can connect with Laura on LinkedIn or Twitter.
Pain Management in Cancer and the Risk of Patients Developing Opioid Use Disorder
As cancer treatments improve and death rates decline, more patients survive who are at risk of becoming addicted to pain medications they were prescribed to treat their cancer-related pain, explained Merrill Norton, PharmD, NCAC II, CCS, CCDP-D, of the University of Georgia.
Designing Best Practices to Better Manage Patients on Oral Cancer Medications
Positive quality interventions are part of a nationwide effort to standardize and improve oncology dispensing practices. They are best practices that are meant to be highly specific to a drug and help pharmacies and clinicians ensure that a patient-centric model exists, explained speakers during a workshop at National Community Oncology Dispensing Association (NCODA) Spring Forum 2018.
Addressing Financial Concerns at the Outset to Improve Patient Outcomes
Being proactive about identifying potential financial burdens and preparing patients who have a disease for the costs of their treatment helps to ensure that patients will be adherent to their medication and have the best possible outcomes, according to a panel of providers at the Cost-Sharing Roundtable, co-hosted by the Patient Access Network Foundation and The American Journal of Managed Care®.
Gender-Affirming Surgeries Increasingly Covered by Private Insurance, Medicare, Medicaid
Since 2000, the number of patients undergoing gender-affirming surgery who identified as self-payers decreased. From 2012-2013 to 2014, coverage by Medicare and Medicaid of gender-affirming surgeries increased 3-fold.
COPD More Prevalent in Rural Areas, CDC Analysis Finds
State variations in chronic obstructive pulmonary disease (COPD) outcomes suggest that the condition is more common in large rural areas compared with metropolitan areas, according to the Morbidity and Mortality Weekly Report from CDC.
HCT Effective for Patients With Non-Hodgkin Lymphoma Regardless of Age
New research has found that allogeneic hematopoietic stem cell transplantation is just as effective in patients with non-Hodgkin lymphoma who are age 65 and older as it is in patients between the ages of 55 and 64.
Early Results From Clinical Trials of Chronic Conditions Are Often Exaggerated
Clinical and policy decisions made using early trial results could be misguided, according to a study that found early results in chronic disease trials are often exaggerated compared with findings in subsequent trials.
Second-Line Nilotinib May Enable Patients With CML to Achieve Treatment-Free Remission
Patients with chronic myeloid leukemia (CML) who have a sustained deep molecular response can maintain treatment-free remission for at least 48 weeks after using second-line nilotinib, according to a new study published in Annals of Internal Medicine.
Working Paper Identifies Hospital Cost Shifting Resulting From Medicare Penalties
A new National Bureau of Economic Research working paper identified potential hospital cost shifting and that hospitals penalized by the Hospital Readmission Reduction Program and the Hospital Value-Based Purchasing Program actually had an increase in average payments of 1.5%.
Discussing the Ethics of Hospital Markups With Dr Martin Makary
In a new letter published in the February issue of The American Journal of Managed Care®, Martin Makary, MD, a professor of surgery at Johns Hopkins University, and his coauthors assessed price markup variation by hospital and by oncology specialty to better understand the financial hardships patients can face when charges for the same service vary widely across hospitals.
FDA Approves Apalutamide, First Treatment for Nonmetastatic Castration-Resistant Prostate Cancer
FDA has approved apalutamide, the first treatment for nonmetastatic castration-resistant prostate cancer, based on results from a phase 3 study that showed the drug reduced the risk of metastasis or death by 72% and improved median metastasis-free survival by more than 2 years.
Patients With COPD Face High Risk of Adverse Drug Reactions Due to Multimorbidity
Multimorbidity is common in patients with chronic obstructive pulmonary disease (COPD), and is associated with high levels of polypharmacy, which can lead to an increased risk of adverse drug reactions.
Senate, House Pass Spending Bill With Health Program Funding After Brief Shutdown
After a brief shutdown in the dead of night, the Senate passed a spending bill, which was the result of a deal reached by Republicans and Democrats to fund military and domestic programs for 2 years. The House passed the bill shortly after.
Long-Term Follow-Up of CAR T in ALL Indicates Early Treatment Extends Survival
A long-term follow-up analyzing the toxic effects and results from a phase 1 clinical trial of adult patients with relapsed B-cell acute lymphoblastic leukemia (ALL) who were treated with CD19-specific chimeric antigen receptor (CAR) T cells found patients with low disease burden had a longer medial overall survival and a lower incidence of toxicity.
Shifting Hospital Care to the Home Improved Quality of Life for Patients With COPD
Shifting care for patients with chronic obstructive pulmonary disease (COPD) from the hospital to the home reduced hospital readmissions by 64% and emergency department visits by 52%, a Canadian program found.
Gut Microbiome Diversity Associated With Blood Infections in Pediatric Patients With Cancer
Every year, central lines are associated with causing blood infections in an estimated 400,000 patients with cancer. However, new research has found that changes in the microbiome may be responsible for some or many of the infections usually attributed to central lines.
Kyprolis Label Gets Updated Improved Survival Data for Patients With Relapsed/Refractory MM
The FDA has approved a supplemental New Drug Application to add new overall survival (OS) data for carfilzomib (Kyprolis). The label will now show that carfilzomib and dexamethasone reduced the risk of death by 21% and increased OS by 7.6 months compared with bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (MM).
Precursor to Blood Cancer Puts Patients at Risk Indefinitely, Study Finds
Despite years of stability, patients with monoclonal gammopathy of undetermined significance (MGUS) are at risk of progressing to multiple myeloma or another blood cancer, according to a long-term follow-up study published in New England Journal of Medicine. MGUS usually causes no problems, but it is a precursor to cancer.